

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Azacitidine for the treatment of myelodysplastic syndrome and acute myeloid leukaemia

Response to consultee and commentator comments on the provisional matrix of consultees and commentators (pre-referral)

Version of matrix of consultees and commentators reviewed:				
Provisional matrix of consultees and commentators sent for consultation				
Summary of comments, action taken, and justification of action:				
	<i>Proposal:</i>	<i>Proposal made by:</i>	<i>Action taken:</i> Removed/Added/Not included/Noted	<i>Justification:</i>
1.	<i>Proposed the following organisation; UK MDS Forum Patient Forum Dr Sally Killick</i>	<i>Royal College of Physicians</i>	<i>Added</i>	<i>MDS UK Patient Forum's interests are closely related to the appraisal topic therefore we have included them in the matrix.</i>
2.	<i>Noted that the manufacturer of the drug are Celgene formerly Pharmion, but never Pfizer.</i>		<i>Added</i>	<i>The comment has been noted and Celgene are the named manufacturer on the matrix</i>

National Institute for Health and Clinical Excellence

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of Azacitidine for the treatment of myelodysplastic syndrome and acute myeloid leukaemia

Issue date: December 2008